MarettyL, GillD, SimonsenL, et al.Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med. 2025; 31(1):267–277. doi: 10.1038/s41591-024-03355-2.
2.
JaraM, NorlinJ, Kj«rMS, et al.Nat Med.Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. 2025. doi: 10.1038/s41591-025-03799-0. Online ahead of print.
